foxo4 dri senolytic peptide human trials inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis FOXO4-DRI FOXO4/p53 Peptide – Peptagon

For additional information or questions regarding New Investigator Updates, Please click here to connect with the right resource to respond

Andrew Huberman recommends pairing the neuropeptide Pinealon with oral glycine to boost REM sleep

First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1375 Per Share for August WHEATON, Ill., July 20, 2026 --(BUSINESS WIRE)--First Trust Intermediate Duration Preferred & Income Fund (the "Fund") (NYSE: FPF) has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1375 per share payable on August 17, 2026, to shareholders of record as of August 3, 2026

Fast-acting injectable for immediate effect Supports energy, immunity, and overall wellness Trusted by health professionals and clinics Easy to administer in professional settings Safe, sterile, and lab-tested Professional-grade B12 for maximum efficacy and client satisfaction